Truly personalized medicine has been a goal for a very long time. The rapidly-falling costs of DNA sequencing and the (re-)emergence of machine learning and other analytics tools are creating a unique opportunity to reshape how medicine and medical research are practiced and care delivered.

This talk will outline how next-generation DNA sequencing and tools developed at companies like LinkedIn and Twitter are enabling a NYC-local biotech company to provide personalized medicine to improve the health of people across the country.

R. Mark Adams

Ph.D.,
Chief Information Officer,
Celmatix

Dr. Adams has been working in bioinformatics and data analytics for more than 20 years, including work in computational biology, biomedicine, intelligence, finance, and biotechnology.

Prior to joining Celmatix, he was the Chief Information Officer for the biotechnology company Good Start Genomics. His previous experience includes Bridgewater Associates, Ltd., where he developed unique data warehousing and machine learning approaches to support the world's largest hedge fund and Booz Allen Hamilton, where as a principal he developed a leading biomedical informatics consulting practice with a primary focus on informatics strategy for clients in the commercial, government, and non-profit markets.

Dr. Adams holds a B.A. from Oberlin College and a PhD. from Baylor College of Medicine.